Buprenorphine-based medications were first approved by the United States Food and Drug
Administration in 2002 for the treatment of opioid dependence, or opioid use disorder (OUD) …

Buprenorphine induction for treating opioid use disorder is being implemented in
emergency care. During this era of high-potency synthetic opioid use, novel and divergent …

Background Induction of buprenorphine, an evidence-based treatment for opioid use
disorder (OUD), has been reported to be difficult for people with heavy use of fentanyl, the …

Low dose buprenorphine initiation, is an alternative method of initiating buprenorphine in
which the starting dose is very low and gradually increased to therapeutic levels over a …

With the worst opioid overdose death crisis in the United States history, urgent new
approaches to assist people who use drugs onto medication for opioid use disorder are …

Objectives: Patients with opioid use disorder (OUD) can initiate buprenorphine without
requiring a withdrawal period through a low-dose (sometimes referred to as “micro …

Abstract Purpose of Review Opioid use disorder (OUD) is a chronic disorder in which a
person loses control over the use of opioids, develops a compulsive behavior, and defends …

Methadone, a full opioid agonist at the mu-, kappa-, and delta-receptor, and buprenorphine,
a partial agonist at the mu receptor, are first-line medications in opioid maintenance …

This paper is the forty-fourth consecutive installment of the annual anthological review of
research concerning the endogenous opioid system, summarizing articles published during …

Objectives Fear and risk of precipitated withdrawal are barriers for initiating buprenorphine
in individuals with opioid use disorder, particularly among those using fentanyl. A …